Vetsina Animal Diagnostics appoints David Whitcombe as Non-Executive Director

Published Wednesday, 4th November 2020

Vetsina Animal Diagnostics – the new company formed by Roslin Technologies and DESTINA Genomics – has announced the appointment of David Whitcombe as Non-Executive Director.

David has more than 10 years of academic research and 15 years in industrial R&D. During his career, he has produced several publications and patents, including the Scorpions technology that formed the basis of his start-up business DxS Ltd in 2000.

David was Head of Technology Development at AstraZeneca Diagnostics for four years leading a team focused on developing new genomic technologies, and successfully developed DxS over eight years before securing an exit in September 2009 for a total enterprise value in excess of £100M.

Vetsina CEO, Dr. Simon Wheeler, said: “We are very pleased that David has joined the board here at Vetsina, he has a lot of highly relevant experience and will be a great asset to the team.”

The appointment follows the sad news of the death of Vetsina founder Hugh Ilyine.

Dr. Wheeler says Hugh was the inspiration that led to the founding of Vetsina Animal Diagnostics: “Hugh led DESTINA Genomics Ltd through a successful period of growth. During that time, through his relationships with academic partners at the University of Edinburgh, he nurtured his enthusiasm for animal science and had the foresight to embark on several projects in animal health using the DESTINA technology. He was greatly respected by the academic colleagues for his intellect, insight and enthusiasm. We will miss Hugh greatly and our thoughts are with his family and former colleagues at DESTINA and beyond.”

ends

Editor’s notes:

About Vetsina Animal Diagnostics

Vetsina Animal Diagnostics has been established to maximise the impact of a revolutionary chemical-based system for detecting nucleic acids and single nucleotide polymorphisms, for the development of simple, fast, accurate & cost-effective products for PCR-free detection of microRNAs in human medicine, by applying it to animal health.

Vetsina will also research the animal diagnostics arena to focus on targets based on market need, technical feasibility and the development of a balanced portfolio.

It was founded by Roslin Technologies and DESTINA Genomics.

About Roslin Technologies

Roslin Technologies is a technology commercialisation company based at Easter Bush Campus, at the centre of the largest concentration of animal science expertise in Europe. The company was created to develop commercial opportunities from the research, know-how, capabilities and intellectual property of The Roslin Institute and The Royal (Dick) School of Veterinary Studies.

Roslin Technologies develop and supply products and services to industry, as well as providing opportunities for investors looking to capitalise on the growing demand for food and agricultural products. For additional information, visit www.roslintech.com.

About DESTINA Genomics

DESTINA Genomics Ltd is a biotech company founded in Edinburgh in 2011 by Hugh Ilyine, Juan J. Diaz-Mochon and Mark Bradley. In July 2012, a Spanish subsidiary DESTINA Genomica S.L. was created with the goal to accelerate a long-term growth plan. The company is focused on the application and validation of its patented state-of-the-art technologies. For additional information, visit https://DESTINAgenomics.com/

For more information contact Mike Keeler (mike.keeler@garnettkeeler.com) or Alistair Moses (alistair.moses@garnettkeeler.com) at Garnett Keeler PR on +44 (0)20 8647 4467. 

Cookie policy

We use necessary cookies to allow our site to function correctly. You can disable these via your browser settings but this site may not function correctly if you do so. We also use optional cookies to collect anonymised visitor statistics to help us identify issues and improve our web site. View our privacy policy here

Cookies